AlphaValue Corporate Services Fundamental Analysis FR
Back to
AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Crossject

CR
Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Some patience (still) required
Target
Upside 232%
Price (€) 3.13
Market Cap (€M) 79.2
Perf. 1W: -2.34%
Perf. 1M: 69.8%
Perf. 3M: 57.2%
Perf Ytd: 9.65%
10 day relative perf. to stoxx600: -9.68%
20 day relative perf. to stoxx600: 80.2%
EPS change31/08/2021

Change in EPS2021 : € -0.28 vs 0.18ns
2022 : € 0.63 vs 0.91-30.7%

We have fine-tuned our numbers on the back of the FY20 detailed accounts. Forecasts were also partly amended but net results remain low in the next few years which explains why a small change in the estimates translates into a more significant one in percentage terms at the EPS level.



Updates

29 Mar 22 Earnings/sales releases
FY21: not very meaningful, as expected

17 Dec 21 Financing issue
New financing

24 Sep 21 Earnings/sales releases
H1 21: unsurprising (as usual)

31 Mar 21 Earnings/sales releases
FY20 unsuprising; waiting for more

15 Dec 20 Financing issue
A double bond issue

12345Next
.